Mass Pharma (Pvt) Ltd.
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based national pharmaceutical manufacturer and marketer with domestic and international operations.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Mass Pharma (Private) Limited
- Company type
- Private pharmaceutical manufacturer
- Address
- 17-KM Ferozepur Road, Lahore, Pakistan
- Website
- masspharma.com ↗
- Phone
- +92 42 35824881-4; +92 322 4873081
- mass@masspharma.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Hitroxin | Ciprofloxacin | 500 mg | IV infusion | 1x10 | 029442 | PKR 520.46 | PKR 52.05/vial/unit | 28% above median |
| Isotrate | Isosorbide mononitrate | 10 mg | Tablet | 3x20 | 016774 | PKR 248.66 | PKR 4.14/tablet | No comparator |
| Isotrate | Isosorbide mononitrate | 20 mg | Tablet | 3x20 | 016775 | PKR 480.81 | PKR 8.01/tablet | 11% above median |
| Isotrate | Isosorbide mononitrate | 40 mg | Tablet | 2x10 | 016776 | PKR 273.41 | PKR 13.67/tablet | 11% above median |
| Itranex | Itraconazole | 100 mg | Capsule | 1x4 | 030877 | PKR 513.00 | PKR 128.25/capsule | 12% below median |
| Levite | Levofloxacin | 250 mg | IV infusion | 1x10 | 032310 | PKR 516.33 | PKR 51.63/vial/unit | No comparator |
| Levite | Levofloxacin | 500 mg | IV infusion | 1x10 | 032311 | PKR 859.17 | PKR 85.92/vial/unit | No comparator |
| Levite | Levofloxacin | 500 mg | IV infusion | 100ml | 038343 | PKR 1,445.71 | PKR 14.46/mL | 180% above median |
| Lopi-Mass | Lopinavir + Ritonavir | 50 mg + 50 mg | Tablet | 12x10 | 106147 | PKR 11,525.21 | PKR 96.04/tablet | 19% below median |
| Lotricort | Betamethasone + Clotrimazole | 0.05 % + 1.0 % | Cream | 15gm | 030873 | PKR 162.09 | PKR 10.81/g | Near median |
| Lotricort Betamethasone Dipro | Clotrimazole | 0.05 % | Cream | 10gm | 030873 | PKR 93.82 | PKR 9.38/g | Near median |
| Lotricort-G | Betamethasone + Clotrimazole | 1 % + 0.1 % | Cream | 15gm | 041697 | PKR 151.42 | PKR 10.09/g | No comparator |
| Lotricort-G Betamethasone | Clotrimazole | 0.05 % | Cream | 10gm | 041697 | PKR 82.30 | PKR 8.23/g | 18% below median |
| Lotrigen | Clotrimazole | 1% | Cream | 15gm | 030869 | PKR 88.27 | PKR 5.88/g | Near median |
| Lotrigen HC | Clotrimazole | 1 % | Cream | 10gm | 062885 | PKR 127.96 | PKR 12.80/g | 107% above median |
| Lumifal | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 2x8 | 054481 | PKR 510.03 | PKR 31.88/tablet | 20% below median |
| Lumifal Plus | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 1x8 | 054482 | PKR 420.78 | PKR 52.60/tablet | 18% below median |
| Maclexin | Cephalexin | 250 mg | Capsule | 1x10 | 020866 | PKR 111.99 | PKR 11.20/capsule | 29% below median |
| Maclexin | Cephalexin | 500 mg | Capsule | 1x10 | 020867 | PKR 224.99 | PKR 22.50/capsule | 27% below median |
| Maclexin | Cephalexin | 125 mg/5 mL | Suspension | 60ml | 020868 | PKR 80.49 | PKR 1.34/mL | 28% below median |
| Maclexin | Cephalexin | 250 mg/5 mL | Suspension | 60ml | 020869 | PKR 129.43 | PKR 2.16/mL | 34% below median |
| Maclexin | Cephalexin | 125 mg | Oral drops | 10ml | 022392 | PKR 88.65 | PKR 8.87/mL | No comparator |
| Malin | Permethrin | 5% | Lotion | 120ml | 048052 | PKR 330.06 | PKR 2.75/mL | Near median |
| Malin | Permethrin | 5 % | Lotion | 60ml | 048052 | PKR 165.22 | PKR 2.75/mL | 5% above median |
| Masdipine | Nifedipine | 20 mg | Sustained-release tablet | 3x10 | 094599 | PKR 287.00 | PKR 9.57/tablet | No comparator |
| Masdipine 30mg SR | Nifedipine | 30 mg | Sustained-release tablet | 2x10 | 094600 | PKR 567.26 | PKR 28.36/tablet | No comparator |
| Masdipine 60mg SR | Nifedipine | 60 mg | Sustained-release tablet | 2x10 | 094601 | PKR 945.43 | PKR 47.27/tablet | No comparator |
| Masplex Plus | Iron protein succinylate + Folic acid | 400 mg + 2.5 mg | Tablet | 2x7 | 069485 | PKR 330.45 | PKR 23.60/tablet | Near median |
| Massvir | Oseltamivir | 75 mg | Capsule | 10's | 110664 | PKR 1,059.50 | PKR 105.95/capsule | 12% below median |
| Mectimite | Ivermectin | 3 mg | Tablet | 2x10 | 057558 | PKR 660.90 | PKR 33.05/tablet | Near median |
| Mectimite | Ivermectin | 6 mg | Tablet | 1x10 | 057559 | PKR 547.31 | PKR 54.73/tablet | Near median |
| Mink | Amikacin | 100 mg | Injection | 2mlx1 | 035502 | PKR 84.68 | PKR 42.34/mL | Near median |
| Mink | Amikacin | 250 mg | Injection | 2mlx1 | 035503 | PKR 136.31 | PKR 68.16/mL | Near median |
| Mink | Amikacin | 500 mg | Injection | 2mlx1 | 035504 | PKR 231.31 | PKR 115.66/mL | Near median |
| Mink | Amikacin | 25 mg | Injection | 1mlx1 | 037730 | PKR 41.31 | PKR 41.31/mL | 11% below median |
| Mink | Amikacin | 50 mg | Injection | 1mlx1 | 037731 | PKR 51.63 | PKR 51.63/mL | 16% above median |
| Mobik | Moxifloxacin | 400 mg | Tablet | 1x5 | 035820 | PKR 994.59 | PKR 198.92/tablet | 8% above median |
| Mobik | Moxifloxacin | 400 mg | Injection | 250ml | 063145 | PKR 2,093.88 | PKR 8.38/mL | No comparator |
| Mupas | Mupirocin | 2% | Ointment | 15gm | 104907 | PKR 217.73 | PKR 14.52/g | Near median |
| Mupas | Mupirocin | 2% | Cream | 15gm | 111060 | PKR 257.10 | PKR 17.14/g | Near median |
| Nelzim . Cephazolin Sodium | Cefazolin | 250 mg | Injection | 1x1 | 027921 | PKR 68.54 | PKR 68.54/vial/unit | 12% below median |
| Nelzim . Cephazolin Sodium | Cefazolin | 1 g | Injection | 1x1 | 027922 | PKR 245.77 | PKR 245.77/vial/unit | 20% above median |
| Neotret | Acitretin | 10 mg | Capsule | 3x10 | 062880 | PKR 967.83 | PKR 32.26/capsule | 19% below median |
| Neotret | Acitretin | 10 mg | Capsule | 2x10 | 062880 | PKR 667.47 | PKR 33.37/capsule | 16% below median |
| Pepzol | Omeprazole | 20 mg | Capsule | 2x7 | 026120 | PKR 234.00 | PKR 16.71/capsule | 15% below median |
| Probase | Bisoprolol fumarate | 5 mg | Tablet | 2x10 | 030880 | PKR 309.80 | PKR 15.49/tablet | 31% above median |
| Probase | Bisoprolol fumarate | 10 mg | Tablet | 2x10 | 030881 | PKR 516.33 | PKR 25.82/tablet | 17% above median |
| Probase | Bisoprolol fumarate | 2.5 mg | Tablet | 14 | 062884 | PKR 68.06 | PKR 4.86/tablet | 15% above median |
| Raban | Rivaroxaban | 10 mg | Tablet | 1x10 | 104911 | PKR 5,522.03 | PKR 552.20/tablet | Near median |
| Raban | Rivaroxaban | 20 mg | Tablet | 14's | 110661 | PKR 12,496.18 | PKR 892.58/tablet | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.